The largest database of trusted experimental protocols

Rat anti cd28 mab

Manufactured by BD
Sourced in United States

Rat anti-CD28 mAb is a monoclonal antibody that targets the CD28 receptor on the surface of T cells. It functions by binding to and regulating the activity of CD28, a key co-stimulatory molecule involved in T cell activation and proliferation.

Automatically generated - may contain errors

2 protocols using rat anti cd28 mab

1

Th17 Cell Polarization Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Isolated PBMCs were divided into six groups and cultured in different media at 1 × 106 cells/ml: 10% control serum + 90% RPMI-1640 medium for the control, model, and hydrocortisone (HC) groups; 10% KJL containing serum + 90% RPMI-1640 medium for the KDH group; 5% KJL containing serum + 5% control serum + 90% RPMI-1640 medium for the KDM group; and 2.5% KJL containing serum + 7.5% control serum + 90% RPMI-1640 medium for the KDL group. Rat anti-CD3 mAb (BioLegend, Inc., USA) and rat anti-CD28 mAb (BD Pharmingen, USA) were used for activation of the T cell in the PBMCs. The 24-well culture plates for PBMC culture were precoated with 5 μg/ml anti-CD3 mAb at 4°C overnight. Anti-CD28 mAb was added into the medium at a final concentration of 2 μg/μl. Polarization towards Th17 cells was induced with 5 ng/ml transforming growth factor-β (TGF-β), 20 ng/ml IL-6, and 25 ng/ml IL-23 (all PeproTech, Inc., USA) in all groups except for the control group, to cause an imbalance between Th17 and Treg cells. For the HC group, 20 ng/ml HC was added into the medium. All groups of cells were cultured under conditions of 5% CO2 and 37°C for 48 h prior to subsequent experiments.
+ Open protocol
+ Expand
2

KJL-mediated T cell activation and viability

Check if the same lab product or an alternative is used in the 5 most similar protocols
Isolated PBMCs were divided into four groups and cultured with different media at 1 × 106 cells/ml: 10% control serum + 90% RPMI-1640 medium for the control group; 10% KJL-containing serum + 90% RPMI-1640 medium for the high KJL dose (KDH) group; 5% KJL-containing serum + 5% control serum + 90% RPMI-1640 medium for the medium KJL dose (KDM) group; and 2.5% KJL-containing serum + 7.5% control serum + 90% RPMI-1640 medium for the low KJL dose (KDL) group. Rat anti-CD3 mAb (BioLegend, Inc., USA) and rat anti-CD28 mAb (BD Pharmingen, USA) were used for activation of the T cells in the PBMCs. The 96-well culture plates for PBMC culture were precoated with 5 μg/ml anti-CD3 mAb at 4°C overnight. Anti-CD28 mAb was added into the medium at a concentration of 2 μg/μl. The cell viability at 12, 24, and 48 h was analyzed using an MTT Cell Proliferation and Cytotoxicity Assay kit (Beijing Solarbio Science & Technology Co., Ltd., China).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!